Jacobson Pharmaceutical (02633.HK) announced its interim results, with a net profit attributable to shareholders of HK$142 million, an increase of 1.24% year-on-year.

Wisdom Financial News APP reports that Jacobson Pharmaceutical (02633.HK) has released its mid-term performance for 2025. The group achieved revenue of 767 million Hong Kong dollars, a decrease of 5.36% compared to the same period last year. The net profit attributable to equity holders of the company was 142 million Hong Kong dollars, an increase of 1.24% year-on-year. Basic earnings per share were 7.12 Hong Kong cents. The mid-term dividend per share was 4.25 Hong Kong cents.